Employees: 11-50
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Illinois V... | illinoisve... |
Mentions in press and media 2
| Date | Title | Description |
| 22.02.2016 | Vanquish Oncology’s small molecule could trigger selective cancer cell death | Last year, the company kicked off Phase 1 trials for PAC-1. The drug works by activating a protein called procaspase-3 that triggers cell death. Vanquish’s small molecule therefore is aimed at kicking off the process of apoptosis in cancer ... |
| - | Vanquish Oncology’s small molecule could trigger selective cancer cell death | A cluster of breast cancer cells undergoing apoptosis, or cell death. Vanquish Oncology is developing a small molecule drug that could trigger selective cell death among cancer cells – while generally leaving the healthy cells alone. Notabl... |